Recall(New to the series?)
Triple agonists activate GLP-1R, GIPR, and GCGR simultaneously. GLP-1 suppresses appetite and slows gastric emptying. GIP synergizes with GLP-1 in fat tissue and the brain to amplify weight loss. Glucagon raises energy expenditure and drives hepatic fat oxidation. For the receptor-by-receptor breakdown, see The Receptor Game.
If dual agonism broke past the semaglutide ceiling, triple agonism is attempting to break past dual agonism's ceiling. The logic is additive: every receptor target adds a distinct mechanism, and combining all three should produce effects none of them achieves alone.
As of mid-2026, one drug occupies this class: retatrutide, in Phase 3 with Eli Lilly.
Retatrutide (LY3437943) — Eli Lilly
At a glance
| Targets | GLP-1R + GIPR + GCGR (triple agonist) |
| Developer | Eli Lilly |
| Modality | Peptide, subcutaneous injection, once-weekly |
| Approval status | Phase 3 (TRIUMPH program) |
| Indications | Obesity, T2D, MASH |
How it works
Retatrutide is a single synthetic peptide engineered to bind and activate all three receptors with distinct potency ratios: GLP-1R (moderate), GIPR (high), GCGR (moderate). The multi-receptor engagement is built into the peptide's amino acid sequence — not a conjugate of separate molecules.
The three mechanisms operate in parallel:
GLP-1R activation — appetite suppression through hypothalamic and brainstem signaling; insulin secretion; gastric slowing. The foundation shared with every drug in this series.
GIPR activation — synergistic amplification of the GLP-1 appetite signal; enhanced fat mobilization from adipose tissue; effects on energy sensing pathways in the brain that GLP-1 alone doesn't fully engage.
GCGR activation — increased resting energy expenditure (the mechanism no single or GLP-1/GIP dual agonist provides); hepatic fat oxidation (the liver-targeting effect relevant to MASH); additional CNS appetite effects. This is the component that theoretically addresses the metabolic adaptation to weight loss — the body's tendency to reduce caloric expenditure as it loses mass.
The glucagon component requires careful dose titration: GCGR activation raises blood glucose through hepatic glucose production, which partially opposes GLP-1's insulin-stimulating effect. At the right ratio, these effects net out. Getting that ratio right across different doses and patient populations is one of the formulation challenges.
Trial data
Phase 2 (TRIUMPH-1, 24 weeks, obesity):
| Dose | Weight loss |
|---|---|
| 1mg | 7.9% |
| 4mg | 17.3% |
| 8mg | 22.8% |
| 12mg | 24.2% |
24.2% mean weight loss is the highest ever recorded in a Phase 2 obesity trial for a non-surgical, non-device intervention. ~100% of participants at the 12mg dose lost at least 5% of body weight; ~83% lost at least 15%.
The dose-response is steep across the range, which suggests the 12mg ceiling may not be the biological maximum. Phase 3 is testing doses up to 12mg with a longer titration schedule.
Phase 2 T2D data: ~2.0% HbA1c reduction at 12mg, along with substantial weight loss, making it the most effective T2D agent in the GLP-1 family on both endpoints simultaneously.
MASH Phase 2: significant hepatic fat reduction consistent with the glucagon agonism mechanism.
Example(Retatrutide vs tirzepatide: the head-to-head question)
No published head-to-head Phase 3 trial between retatrutide and tirzepatide yet, but the Phase 2 comparison is instructive: tirzepatide SURMOUNT-1 showed 20.9% at 72 weeks; retatrutide Phase 2 showed 24.2% at 24 weeks (shorter duration). Direct comparison is difficult due to trial design differences, but the magnitude suggests retatrutide's triple mechanism adds roughly 3–5 percentage points of weight loss over tirzepatide's dual mechanism. Phase 3 data at longer duration and with a head-to-head design would clarify this.
Dosing and administration
Subcutaneous injection, once weekly. Titration schedule starting at 2mg with dose escalation every 4 weeks toward the 8mg or 12mg maintenance doses. The slow titration is designed to manage GI side effects (from GLP-1R) and glucagon-mediated glucose excursions during ramp-up.
Phase 3 TRIUMPH program is testing both 8mg and 12mg maintenance doses with extended 72-week timeframes.
Development status
| Milestone | Status |
|---|---|
| Phase 2 obesity | Complete — 24.2% weight loss at 24 weeks |
| Phase 3 TRIUMPH (obesity) | Enrolling — results expected 2026–2027 |
| Phase 3 T2D | Enrolling |
| Phase 3 MASH | Enrolling |
| FDA filing | Pre-submission — NDA expected ~2027 |
Lilly has strong manufacturing infrastructure from tirzepatide production, which reduces the supply chain risk that affected Wegovy's launch.
Safety profile
Phase 2 tolerability was broadly consistent with the GLP-1 class: nausea and vomiting most common during titration, self-resolving in most participants. The glucagon component raises theoretical concern about hyperglycemia in non-diabetic patients, but Phase 2 data showed this was manageable within the dose range tested. Heart rate increase (also seen with other GLP-1RA) was observed. No new safety signals specific to the triple mechanism identified in Phase 2.
Phase 3 data will be the real tolerability read at longer duration and with the full intended population.
Is there a ceiling above triple agonism?
The incremental gain from single → dual → triple agonism raises the question of where the ceiling is. Adding a fourth receptor target is theoretically possible — amylin receptor co-agonism (the approach CagriSema takes through separate components) is one candidate. But each additional target adds regulatory, tolerability, and formulation complexity.
The more likely direction: refining the ratio of existing targets, developing oral triple agonists, and combining triple agonism with complementary mechanisms (amylin, peripherally-acting agents) rather than adding a fourth receptor to the peptide.
Summary(Family summary)
Triple agonism has one drug and one set of Phase 2 numbers that are the highest in the field. Retatrutide's 24.2% weight loss at Phase 2 represents the current efficacy frontier for pharmacological obesity treatment. Phase 3 will determine whether that holds, and whether the tolerability profile is acceptable at scale. If both answers are yes, triple agonism becomes the new ceiling the next generation will try to break.